Business Context and Reporting Period
This Form 8-K is a current report filed by Miragen Therapeutics, Inc. (not Viridian Therapeutics, Inc.) on April 29, 2019. The registrant is a Delaware corporation headquartered in Boulder, Colorado, and is classified as an emerging growth company. The filing reports on a specific corporate event rather than a standard financial reporting period.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a scientific development update and does not contain financial statements or quantitative financial data.
Material Changes
The material event reported is the issuance of a press release on April 29, 2019, announcing new data from a preclinical study. The study evaluated remlarsen, a microRNA-29 replacement, specifically exploring its anti-fibrotic effects in the cornea of rats following corneal ulceration.
Guidance, Outlook, and Risks
The filing incorporates a press release (Exhibit 99.1) detailing the preclinical study results. No specific financial guidance, forward-looking revenue projections, or management commentary regarding financial outlook is included in this text. The filing does not explicitly list new risks or contingencies beyond the inherent uncertainties of preclinical research.
Investor Verification Checklist
- Verify the full details of the preclinical study results in the attached press release (Exhibit 99.1).
- Confirm the regulatory status and development timeline for remlarsen following this corneal ulceration data.
- Review the company's most recent 10-K or 10-Q for actual financial position, cash runway, and liquidity metrics, as they are absent here.
- Note the discrepancy between the requested company name (Viridian Therapeutics) and the filing registrant (Miragen Therapeutics).